URIST MARSHALL (EVP & Co-Head Research & Inv.) sold 16.7% of their position (20K shares) of ROYALTY PHARMA PLC on the open market
Open‑market sale worth $786.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 12/29/2025ACC: 0001838139-25-000014
Officer· EVP & Co-Head Research & Inv.
Since Dec 2020
-20K
Net shares
Net seller
$786.4K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
20K disposed
Non-Derivative Transactions1
Class A Ordinary Shares
Indirect
Shares
−20K
Price / share
$39.32
Trade value
$786.38K
% of position
16.7%
12/26/2025
120K→100K
Total
Net shares
−20K
Net value
-$786.38K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Shares Indirect | 12/26/2025 | S · Sale | −20K | $39.32 | $786.38K | 16.7% | 120K | 100K |
| Total | −20K | -$786.38K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Class A Ordinary Shares
IndirectShares owned19.02K
Class A Ordinary Shares
DirectShares owned7.40K
Total
7.40K direct·19.02K indirect26.42K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Ordinary Shares | 19.02K | Indirect |
| Class A Ordinary Shares | 7.40K | Direct |
| Total | 26.42K | 7.40K direct·19.02K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported